H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Assertio (ASRT) to $21.80 from $18 and keeps a Neutral rating on the shares. The firm cites Garda Therapeutics’ increased takeout offer for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT:
- Assertio Agrees to Enhanced All-Cash Acquisition by Garda
- Garda amends agreement to acquire Assertio to $21.80 per share in cash
- Assertio Extends Garda Tender Offer Commencement Deadline
- Assertio, Garda mutually agree to extend tender offer deadline
- Assertio Therapeutics Faces Garda Tender Offer After Window-Shop